Therapeutic uses of dehydroepiandrosterone

Current Opinion in Investigational Drugs

Volumn 4, Issue 10, 2003, Pages 1205-1208

  Hinson, Joy P ^a   Brooke, Antonia ^a   Raven, Peter W ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Adrenal insufficiency; Aging; Depression; Immune function; Osteoporosis; SLE

Indexed keywords

HEPATITIS B VACCINE; INFLUENZA VACCINE; PLACEBO; PRASTERONE; STEROID; TAMOXIFEN; TETANUS TOXOID;

ACNE; ADRENAL INSUFFICIENCY; AGING; BONE DENSITY; BONE MINERAL; BREAST CANCER; CANCER GROWTH; CHRONIC INFLAMMATION; CLINICAL TRIAL; DEPRESSION; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG USE; HEPATITIS B; HIRSUTISM; HORMONE SUBSTITUTION; HUMAN; HYPERHIDROSIS; IMMUNITY; IMMUNOMODULATION; INFLUENZA; LONG TERM CARE; MENTAL DISEASE; METABOLISM; NONHUMAN; ODOR; OSTEOPOROSIS; REVIEW; SENESCENCE; SIDE EFFECT; SKIN DISEASE; TETANUS; VACCINATION;

ADRENAL INSUFFICIENCY; AGING; ANIMALS; BONE DENSITY; CHRONIC DISEASE; DEHYDROEPIANDROSTERONE; HUMANS; IMMUNITY; INFLAMMATION; MENTAL DISORDERS;

EID: 0242658570     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Shealy CN: A review of dehydroepiandrosterone (DHEA). Integ Physiol Behav Sci (1995) 30(4):308-313.
2. Hinson JP, Raven PW: DHEA deficiency syndrome: A new term for old age? J Endocrinol (1999) 163(1):1-5.
3. Riedel M, Wiese A, Schurmeyer TH, Brabant G: Quality of life in patients with Addison's disease: Effects of different cortisol replacement modes. Exp Clin Endocrinol (1993) 101(2):106-111.
4. Burman P, Broman JE, Hetta J, Wiklund I, Erfurth EM, Hagg E, Karlsson FA: Quality of life in adults with growth hormone (GH) deficiency: Response to treatment with recombinant human GH in a placebo-controlled 21-month trial. J Clin Endocrinol Metab (1995) 80(12):3585-3590.
5. Johannsson G, Burman P, Wiren L, Engstrom BE, Nilsson AG, Ottosson M, Jonsson B, Bengtsson BA, Karlsson FA: Low dose dehydroepiandrosterone affects behaviour in hypopituitary androgen-deficient women: A placebo-controlled trial. J Clin Endocrinol Metab (2002) 87(5):2046-2052.
6. Gebre-Medhin G, Husebye ES, Mallmin H, Helstrom L, Berne C, Karlsson FA, Kampe O: Oral dehydroepiandrosterone (DHEA) replacement therapy in women with Addison's disease. Clin Endocrinol (2000) 52(6):775-780.
7. Hunt PJ, Gurnell EM, Huppert FA, Richards C, Prevost AT, Wass JA, Herbert J, Chatterjee VK: Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomised double blind trial. J Clin Endocrinol Metab (2000) 85(12):4650-4656.
8. Arlt W, Callies F, Van Vlijmen JC, Koehler I, Reincke M, Bidlingmaier M, Huebler D, Oettal M, Ernst M, Schulte HM, Allolio B: Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Eng J Med (1999) 341(14):1013-1020. The first controlled study of DHEA replacement in adrenal insufficiency is described.
9. Callies F, Fassnacht M, Van Vlijmen JC, Koehler I, Huebler D, Seibel MJ, Arlt W, Allolio B: Dehydroepiandrosterone replacement in women with adrenal insufficiency: Effects on body composition, serum leptin, bone turnover, and exercise capacity. J Clin Endocrinol Metab (2001) 86(5):1968-1972.
10. Lovas K, Gebre-Medhin G, Trovik TS, Fougner KJ, Uhlving S, Nedrebo BG, Myking OL, Kampe O, Husebye ES: Replacement of dehydroepiandrosterone in adrenal failure: No benefit for subjective health status and sexuality in a 9 month, randomised, parallel group clinical trial. J Clin Endocrinol Metab (2003) 88(3):1112-1118.
11. Barrett-Connor E, von Muhlen D, Laughlin GA, Kripke A: Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: The Rancho Bernado Study. J Am Geriatr Soc (1999) 47(6):685-691.
12. Schmidt PJ, Murphy JH, Haq N, Danaceau MA, St Clair L: Basal plasma hormone levels in depressed perimenopausal women. Psychoneuroendocrinology (2002) 27(8):907-920.
13. Heuser I, Deuschle M, Luppa P, Schweiger U, Standhardt H, Weber B: Increased diurnal plasma concentrations of dehydroepiandrosterone in depressed patients. J Clin Endocrinol Metab (1998) 83(9):3130-3133.
14. Morrison MF, Ten Have T, Freeman EW, Sammel MD, Grisso JA: DHEA-S levels and depressive symptoms in a cohort of African American and Caucasian women in the late reproductive years. Biol Psychiatry (2001) 50(9):705-711.
15. Young AH, Gallagher P, Porter RJ: Elevation of the cortisol-dehydroepiandrosterone ratio in drug-free depressed patients. Am J Psychiatry (2002) 159(7):1237-1239.
16. Kaminska M, Harris J, Gijsbers K, Dubrovsky B: Dehydroepiandrosterone sulfate (DHEAS) counteracts decremental effects of corticosterone on dentate gyrus LTP. Implications for depression. Brain Res Bull (2000) 52(3):229-234.
17. Wolkowitz OM, Reus VI, Roberts E, Manfredi F, Chan T, Raum WJ, Ormiston S, Johnson R, Canick J, Brizendine L, Weingartner H: Dehydroepiandrosterone (DHEA) treatment of depression. Biol Psychiatry (1997) 41(3):311-318.
18. Wolkowitz OM, Reus VI, Keebler A, Nelson N, Friedland M, Brizendine L, Roberts E: Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry (1999) 156(4):646-649. Reports a randomized controlled trial demonstrating the positive effects of DHEA treatment.
19. Strous RD, Maayan R, Lapidus R, Stryjer R, Lustig M, Kotler M, Weizman A: Dehydroepiandrosterone augmentation in the management of negative, depressive and anxiety symptoms in schizophrenia. Arch Gen Psychiatry (2003) 60(2):133-141.
20. 1 receptor agonists. Drugs News Perspect (2002) 15(10):617-625.
21. Wolkowitz OM, Kramer JH, Reus VI, Costa MM, Yaffe K, Walton P, Raskind M, Peskind E, Newhouse P, Sack D, De Souza E et al: DHEA treatment of Alzheimer's disease: A randomized, double-blind, placebo-controlled study. Neurology (2003) 60(7):1071-1076.
22. Gordon CM, Grace E, Emans SJ, Feldman HA, Goodman E, Becker KA, Rosen CJ, Gundberg CM, LeBoff MS: Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: A randomized trial. J Clin Endocrinol Metab (2002) 87(11):4935-4941. This study demonstrated that DHEA is more effective than conventional HRT in treating anorexia nervosa.
23. Greendale GA, Edelstein S, Barret-Connor E: Endogenous sex steroids and bone mineral density in older women and men: The Rancho Bernado Study. J Bone Miner Res (1997) 12(11):1833-1843.
24. Morales AJ, Nolan JJ, Nelson JC, Yen SSC: Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab (1994) 78(6):1360-1367. The first randomized controlled trial of the effects of DHEA treatment in older individuals is reported.
25. Labrie F, Diamond P, Cusan L, Gomez JL, Belanger A, Candas B: Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina and endometrium in postmenopausal women. J Clin Endocrinol Metab (1997) 82(10):3498-3505. This study, although open label, was longer than most others and used topically applied DHEA.
26. Marcelli C: Can DHEA be used to prevent bone loss and osteoporosis? Joint Bone Spine (2003) 70(1):1-2. An important and recent review of DHEA and osteoporosis.
27. Van Vollenhoven RF: Dehydroepiandrosterone for the treatment of systemic lupus erythematosus. Expert Opin Pharmacother (2002) 3(1):23-31. Am important of DHEA and SLE. This research group have conducted most of the clinical work in this area.
28. Chang DM, Lan JL, Lin HY, Luo SF: Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: A multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2002) 46(11):2924-2927.
29. Andus T, Klebl F, Rogler G, Bregenzer N, Scholmerich J, Straub RH: Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: A pilot study. Aliment Pharmacol Ther (2003) 17(3):409-414.
30. Svec F, Porter JR: The actions of exogenous dehydroepiandrosterone in experimental animals and humans. Proc Soc Exp Biol Med (1998) 218(3):174-191. This review gives a comprehensive account of all the actions of DHEA reported since 1998.
31. Loria RM: Immune up-regulation and tumor apoptosis by androstene steroids. Steroids (2002) 67(12):953-966.
32. Casson PR, Andersen RN, Herrod HG, Stentz FB, Straughn AB, Abraham GE, Buster JE: Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. Am J Obstet Gynecol (1993) 169(6):1536-1539.
33. Khorram O, Vu L, Yen SS: Activation of immune function by dehydroepiandrosterone (DHEA) in age-advanced men. J Gerontol A Biol Sci Med Sci (1997) 52(1):M1-M7.
34. Fulop T Jr, Wagner JR, Khalil A, Weber J, Trottier L, Payette H: Relationship between the response to influenza vaccination and the nutritional status in institutionalized elderly subjects. J Gerontol A Biol Sci Med Sci (1999) 54(2):M59-M64.
35. Danenberg HD, Ben-Yehuda A, Zakay-Rones Z, Gross DJ, Friedman G: Dehydroepiandrosterone treatment is not beneficial to the immune response to influenza in elderly subjects. J Clin Endocrinol Metab (1997) 82(9):2911-2914.
36. Somekh E, Dagan R, Hanukoglu A: The effect of endogenous dehydroepiandrosterone sulphate on antibody response to hepatitis B vaccine in neonates. Isr Med Assoc J (2000) 2(3):200-202.
37. Evans TG, Judd ME, Dowell T, Poe S, Daynes RA, Araneo BA: The use of oral dehydroepiandrosterone sulfate as an adjuvant in tetanus and influenza vaccination of the elderly. Vaccine (1996) 14(16):1531-1537.
38. Degelau J, Guay D, Hallgren H: The effect of DHEAS on influenza vaccination in aging adults. J Am Geriatr Soc (1997) 45(6):747-751.
39. Ben-Yehuda A, Danenberg HD, Zakay-Rones Z, Gross DJ, Friedman G: The influence of sequential annual vaccination and of DHEA administration on the efficacy of the immune response to influenza vaccine in the elderly. Mech Ageing Dev (1998) 102(2-3):299-306.
40. Arlt W, Callies F, Koehler I, Van Vlijmen JC, Fassnacht M, Strasburger CJ, Seibel MJ, Heubler D, Ernst M, Oettel M, Reincke M et al: Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion. J Clin Endocrinol Metab (2001) 86(10):4686-4692.
41. Vogiatzi MG, Boeck MA, Vlachopapodopoulou E, El-Rashid R, New MI: Dehydroepiandrosterone in morbidly obese adolescents: Effects on weight, body composition, lipids and insulin resistance. Metabolism (1996) 45(8):1011-1015.
42. Lasco A, Frisina N, Morabito N, Gaudio A, Morini E, Trifiletti A, Basile G, Nicita-Mauro V, Cucinotta D: Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. Eur J Endocrinol (2001) 145(4):457-461.
43. Schriock ED, Buffington CK, Givens JR, Buster JE: Enhanced postreceptor insulin effects in women following dehydroepiandrosterone infusion. J Soc Gynecol Investig (1994) 1(1):74-78.
44. Stoll BA: Dietary supplements of dehydroepiandrosterone in relation to breast cancer risk. Eur J Clin Nutr (1999) 53(10):771-775. A review of breast cancer risk in relation to DHEA administration; This review urges caution in the use of DHEA.
45. Dorgan JF, Longcope C, Stephenson HE Jr, Falk RT, Miller R, Franz C, Kahle L, Campbell WS, Tangrea JA, Schatzkin A: Serum sex hormone levels are related to breast cancer risk in postmenopausal women. Environ Health Perspect (1997) 105(Suppl 3):583-585.
46. Calhoun K, Pommier R, Cheek J, Fletcher W, Toth-Fejel S: The effects of high dehydroepiandrosterone sulfate levels on tamoxifen blockade and breast cancer progression. Am J Surg (2003) 185(5):411-415.
47. Labrie F, Luu-The V, Labrie C, Belanger A, Simard J, Lin S-X, Pelletier G: Endocrine and intracrine sources of androgens in women: Inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev (2003) 24(2):152-182. This review gives a very positive view of the uses of DHEA. Strongly argues against significant cancer risk from DHEA use.